EG Capital Group

Presto is a technology company that specializes in providing advanced digital solutions to the hospitality industry, particularly in automating operations for drive-thrus. Founded at M.I.T. in 2008 and headquartered in Silicon Valley, California, Presto leverages voice, vision, and touch technologies to enhance guest experiences and help businesses address labor shortages. The company has shipped over 250,000 systems, making it one of the largest providers of labor automation technology in its sector. Its customer base includes many of the top 20 restaurant chains in the United States, where Presto's solutions contribute to generating new revenue and streamlining operations.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates aimed at targeting and eliminating disease-causing proteins for the treatment of cancer, neurodegenerative diseases, and other conditions. The company's lead product candidate, CFT7455, is an orally bioavailable degrader targeting IKZF1/3, designed to treat multiple myeloma and various lymphomas. Additionally, C4 Therapeutics is advancing CFT8634, which targets BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors, as well as programs targeting BRAF V600E and RET for genetically defined resistant solid tumors. The company employs its proprietary Degronimid platform, which utilizes small molecule binders to flag harmful proteins for degradation by the cellular proteasome system, allowing for the potential treatment of previously undruggable targets. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics engages in strategic collaborations to enhance its research and development efforts.